SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as an UBS upgrade sparked bullish sentiment, with the community eyeing a potential short squeeze and significant gains. Traders are closely watching NIO Day and ES8 deliveries, drawing comparisons to other EV manufacturers like Tesla. The stock is facing resistance, but many believe it has the potential to reach much higher prices.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending amid high volume and community excitement, fueled by speculation of upcoming government contracts. A recent congressional disclosure of stock purchases by a politician and Goldman Sachs increasing their holdings has further amplified the buzz. Traders are closely watching key resistance levels, anticipating a potential short squeeze and aiming for significant gains.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the company received UK regulatory approval for its acquisition of Oxford Ionics, potentially accelerating its technology roadmap; the community is actively discussing the deal's implications and future catalysts such as the Quantum World Congress. Bullish sentiment is fueled by analyst upgrades, increased price targets, and perceived momentum in the quantum computing sector, while bears question the valuation and long-term profitability.

Lazydays Holdings, Inc. retails recreational vehicles, motorcycles, jet skis and related accessories. The company operates recreation vehicle dealerships, generating revenue by providing RV owners a full spectrum of products: RV sales, RV services, financing and insurance products, RV parts and accessories, RV rentals, third-party protection plans, and RV camping. Lazydays Holdings was founded in 1976 and is headquartered in Tampa, FL.

Lazydays Holdings Inc

Lazydays Holdings ($GORV) is trending due to a recent acquisition announcement and a letter of intent with Campers Inn, including consideration for furniture and equipment. The community is actively discussing the potential impact of this acquisition, with some speculating about a pump and dump, while others are encouraged by the company's book value. Discussions also include the possibility of future offerings and price targets.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to a significant $53 million contract to deploy solar storage projects, sparking excitement about the company's growth potential in the energy sector. Community discussions revolve around the stock's volatile price action, potential short squeeze opportunities, and comparisons to other high-flying stocks. Some traders are also noting its low float, which may contribute to price swings.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to its low float and potential for a short squeeze, mirroring the recent movements of other low-float stocks. The community is actively discussing its high trading volume relative to its float, with some suggesting it could reach new highs. Several users are pointing to the company's fundamentals, such as cash position and lack of debt, as reasons for potential growth.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as the community discusses its potential inclusion in the S&P 500 and the possibility of acquiring TikTok. Bullish sentiment is fueled by analysts raising price targets and expansion into international markets, while some traders are eyeing a potential pullback from recent highs and expressing concerns about overvaluation and manipulation.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as community members highlight its strength within the defense sector and potential for further gains, with some eyeing triple-digit prices. A catalyst appears to be related to upcoming events and potential news, leading to discussions around its involvement in key defense programs. Investors are actively discussing its valuation, growth prospects, and potential contracts within the broader context of increasing defense spending.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards HPC/AI, drawing comparisons to other miners already in the space like $IREN and $CIFR. Community members are weighing the company's existing Bitcoin mining operations against opportunities in the AI sector, while also noting a high short interest and potential for a short squeeze. Some traders are monitoring borrowing fees and levels, while others discuss technical indicators and potential price movements related to broader market trends.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending amid discussions around recent executive stock sales, a completed acquisition, and revised financial guidance, leading to mixed sentiment. While some investors express frustration over the stock's volatile behavior and perceived mismanagement, others remain bullish, pointing to the company's long-term potential and strategic moves. Community talking points include potential catalysts, market manipulation, and the impact of institutional ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

U.S. equities declined in Tuesday’s midday trade, with the crucial two-day Federal Open Market Committee (FOMC) meeting currently underway.Ahead of the release of the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-meeting-date-fomc-rate-decision-when-announce-what-to-expect/chwynHURdzn">Fed meeting's outcome</a>, President Donald Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-fed-should-be-independent-should-listen-to-smart-people-like-me/chwylmVRdzX">called on</a> the central bank to listen to “smart people” like himself, while stating that the central bank should remain independent.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.16% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.11%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.26%.Here are the top stocks making the biggest moves in Tuesday’s midday trade:<a href="https://stocktwits.com/symbol/BBAI">BigBear.ai Holdings Inc. (BBAI)</a>BigBear.ai shares were up more than 15% in Tuesday’s midday trade after a recent&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bigbear-sparks-retail-buzz-as-congressional-disclosure-fuels-federal-win-rumor/chwy743RdyX">disclosure</a> by Representative Lisa McClain (R-Mich.) regarding the purchase of BBAI stock worth between $15,000 and $50,000 as part of a 401K account held with Charles Schwab. BigBear.ai was the top trending stock on Stocktwits at the time of writing.<a href="https://stocktwits.com/symbol/BBAI">BBAI stock</a> is up 32% year-to-date.<a href="https://stocktwits.com/symbol/TSLA">Tesla Inc. (TSLA)</a>Tesla shares continued to rise, gaining nearly 3% in Tuesday’s midday session following a surge on Monday after co-founder and CEO Elon Musk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-shares-surge-elon-musk-purchases-stock-first-time-since-2020/chwwIvpRdUG">acquired</a> 2.57 million shares of the company on Friday, at an aggregate value of nearly $1 billion.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is up 4% year-to-date.<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health Inc. (HIMS)</a>Hims &amp; Hers Health shares dropped by over 7% in Tuesday’s midday trade after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">sent</a> a letter alleging that the company’s claims concerning compounded Semaglutide products, used for weight loss, are “false or misleading.”<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is up 109% year-to-date.<a href="https://stocktwits.com/symbol/RKLB">Rocket Lab Corp. (RKLB)</a>Rocket Lab shares dropped over 12% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-tumbles-10-percent-today-here-is-what-happened/chwyZ66Rdzl">announced</a> a $750 million at-the-market (ATM) equity offering.<a href="https://stocktwits.com/symbol/RKLB">RKLB stock</a> is up 87% year-to-date.<a href="https://stocktwits.com/symbol/WBD">Warner Bros. Discovery Inc. (WBD)</a>Warner Bros. Discovery shares fell over 8% in Tuesday’s midday trade after analysts at TD Cowen downgraded the stock to ‘Hold’ from ‘Buy’ on concerns that “there would be a lot of hurdles” in Paramount Skydance Corp.’s (PSKY)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-reportedly-plans-majority-cash-bid-for-warner-bros-discovery/chwNp8zRdvx">reported</a> bid to acquire the former, according to TheFly. Senator Elizabeth Warren on Tuesday also voiced her disapproval, calling to block the deal, and said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ewarren/status/1967936711264272677">post</a> on X that it “would be a dangerous concentration of power over our media and news.”<a href="https://stocktwits.com/symbol/WBD">WBD stock</a> is up 69% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-meeting-date-fomc-rate-decision-when-announce-what-to-expect/chwynHURdzn">Fed Meeting Date: Here's When FOMC's Rate Decision Will Be Announced, And What You Should Expect</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

BigBear.ai, Tesla, Hims & Hers, Rocket Lab, Warner Bros Discovery: Stocks Making The Biggest Moves Today

BigBear.ai shares were up more than 15% on Tuesday after a recent disclosure by Representative Lisa McClain regarding the purchase of BBAI stock worth between $15,000 and $50,000.

Equity

Shares of Hims &amp; Hers Health (HIMS) slumped 7% on Tuesday after the U.S. Food and Drug Administration (FDA) sent a letter to the company CEO regarding the sale of compounded drug products.In the letter <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-09092025">dated</a> September 9, the agency alleged that the company’s claims concerning compounded Semaglutide products, used for weight loss, are “false or misleading.” The FDA also noted that this is a violation of certain sections of the Federal Food, Drug, and Cosmetic Act.The FDA pointed out that compounded drug products are not approved by it. “Your claims imply that your products are the same as an FDA-approved product when they are not,” the letter said, while urging the company to take immediate action to address violations. A failure to adequately address any violation may result in legal action without further notice, it added.The FDA further alleged that these compounded products are misbranded and noted that the introduction of misbranded products into interstate commerce is prohibited. While the letter referred to two claims made on compounded Semaglutide products made on Hims’ website, it does not represent an exhaustive list of misbranding violations, the agency said.The FDA has given CEO Andrew Dudum 15 working days from the receipt of the letter to provide a written response describing the steps taken to address violations or to provide reasoning and supporting information if he believes the company is not in violation.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped from ‘bullish’ to 'extremely bullish' territory over the past 24 hours, while message volume stayed at ‘high’ levels.In June, Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-plunges-after-novo-nordisk-ends-wegovy-partnership/chm55y3RR5v">said</a> that it is halting collaboration with Hims &amp; Hers for the sale of its blockbuster weight loss drug Wegovy, the key ingredient of which is Semaglutide. Novo said that Hims &amp; Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It further alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions of Wegovy and has hence decided to halt the collaboration entered into in late April.Dudum, however, subsequently <a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-hits-back-at-novo-nordisk-after-collaboration-end/chm5fs2RRd4">alleged</a> that Novo’s management is “misleading the public.” The CEO stated in a post on X that the pharmaceutical company’s commercial team has been pressuring the company to control clinical standards and steer patients toward Wegovy, regardless of whether it is clinically the best option for patients.HIMS stock has more than doubled its value this year and tripled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened

In a letter dated September 9, the FDA alleged that the company’s claims concerning compounded Semaglutide products are “false or misleading.”

Hims & Hers Expands AI and Technology Focus to Advance Digital Care

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

Company News for Sep 16, 2025

Companies in The News Are: NVDA,HIMS,MSFT,NFLX

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $54.03, signifying a -2.65% move from its prior day's close.

OMCL or HIMS: Which Is the Better Value Stock Right Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.

The last few months have seen a resurgence in social media-driven stock trades,&nbsp;resulting in a crop of new meme stocks,&nbsp;including Opendoor, GoPro, Kohl's, and Krispy Kreme.Now, JPMorgan has identified a few more names to keep a tab on. "We are flagging a few stocks that are heavily mentioned on Social Media and have high Retail buying as well as high Hedge fund Shorting," the investment research said in a note to clients, according to<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/09/11/four-meme-stocks-with-high-social-activity-and-hedge-funds-shorts-according-to-jpmorgan.html">&nbsp;CNBC</a>. "These stocks may experience unexpected flows in case of increased activity."Here are JPMorgan's picks and brief notes on their recent moves:&nbsp;Hims &amp; Hers HealthThe weight loss and health management company's stock has fluctuated significantly between peaks and troughs. Earlier this year, the company entered into a partnership with Novo Nordisk to distribute the latter's Wegovy, a popular GLP-1 weight loss drug. However, a few months later, the Danish pharmaceutical major canceled the partnership, citing Hims &amp; Hers' failure to prevent "knockoff" compounded versions of Wegovy and for engaging in deceptive marketing.U.S. regulators have rapped Hims &amp; Hers for its drug marketing practices, and investors are closely watching the company's moves.Year-to-date gain: 110%Short interest: 31.1%Stocktwits sentiment:&nbsp;Bullish&nbsp;ImmunityBioThe cancer-focused biotech firm has seen interest, driven by clinical-stage Anktiva,&nbsp;designed to boost the immune system's tumor-fighting response, and&nbsp;immunotherapies that target and kill cancer cells. Although the company's stock has mostly&nbsp;traded rangebound this year, shares have jumped double-digit percentages on several occasions in reaction to positive trial data.Year-to-date gain: 0.4%Short interest: 8%Stocktwits sentiment:&nbsp;Bullish&nbsp;Rocket CompaniesThe mortgage and house-owning services firm has seen its stock climb steadily this year, with a recent bump accompanying renewed expectations of a potential lowering of interest rates. The stock hit a 52-week high earlier this week.In March, the Rocket Companies announced a massive $9.4-billion all-stock acquisition of competitor Mr. Cooper Group, lifting investor confidence. The company's business is closely tied to the housing market, which is experiencing a modest rebound.Year-to-date gain: 97%Short interest: 5.3%Stocktwits sentiment:&nbsp;Bullish&nbsp;SoundHound AIAfter a whopping 836% rise in 2024, SoundHound shares have traded comparatively sombrely this year. That said, several analysts have recently begun covering the company, impressed by its voice-based AI technology.In July, the company reported a 217% rise in its second-quarter revenue and increased its sales guidance for the whole year.Year-to-date loss: 29%Short interest: 28.7%Stocktwits sentiment:&nbsp;Bullish&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/rent-the-runway-stocks-plummets-27-after-hours-on-mounting-losses-surging-costs-retail-traders-still-bullish/chw8hPeRdwL">&nbsp;Rent The Runway Stocks Plummets 27% After-Hours On Mounting Losses, Surging Costs — Retail Traders Still Bullish</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 26, 2025, in New York City. 

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

Meme mania has resurged in the past few months.

Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 3% on Wednesday after the telehealth company launched a new category in men’s health, offering access to innovative, affordable, and personalized treatment plans for low testosterone.The company estimates that over 20 million men in the U.S. struggle with low testosterone, but noted that most never receive care due to stigma, outdated treatments, and high costs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> stayed within the ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels. According to Stocktwits data, retail chatter around the stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.<figure class="image"><img style="aspect-ratio:624/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_12_36_35_PM_png_dcb797f889.webp" alt="HIMS's Sentiment Meter and Message Volume as of 12:36 p.m. ET on Sept. 10, 2025 | Source: Stocktwits" width="624" height="61"><figcaption>HIMS' Sentiment Meter and Message Volume as of 12:36 p.m. ET on Sept. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that the stock continues to rally without offering a favorable entry point.<stembedurl>https://stocktwits.com/Canyonfundstrader2007/message/628171596</stembedurl>Hims <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.hims.com/news/news-details/2025/Hims-Launches-New-Category-in-Mens-Health-with-Exclusive-Branded-Oral-Testosterone-and-Expanded-Personalized-Treatments/default.aspx">said</a> on Wednesday that low testosterone, if left untreated, can drain energy, dull mood and sexual desire, and raise risks of heart disease, diabetes, and cancer. Starting in 2026, the company will launch a branded oral testosterone called Kyzatrex through a collaboration with Marius Pharmaceuticals. Kyzatrex is FDA-approved and has been shown to restore testosterone levels in up to 96% of men, Hims said.The company also stated that it will introduce access to injectable testosterone treatments in 2026. Providers will also be able to prescribe tailored doses of compounded Enclomiphene for men experiencing sexual symptoms through the Hims &amp; Hers platform starting Wednesday, the company said. Enclomiphene has been shown to double testosterone levels by restoring natural testosterone production, the company stated. Bloomberg <a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-to-launch-low-testosterone-treatments-for-men-as-weight-loss-drug-sales-slow/chwjw9LRdt6">reported</a> that Hims will make the announcement earlier in the day.&nbsp;Separately, on Tuesday, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced a major reform of pharmaceutical advertisements, which will require drug companies to include full safety warnings in their direct-to-consumer ads.According to BofA analyst Allen Lutz, these industry changes are likely to make new customer conversions more challenging through ads, given the competitive pressures in the sexual health, hair loss, and weight loss sectors. Overall, Hims &amp; Hers should be able to navigate this environment given its strong brand equity and first-mover advantage, the analyst said, while adding that it would expect continued volatility in the near term.The firm kept an ‘Underperform’ rating on Hims &amp; Hers with a price target of $28 on the shares.HIMS stock has more than doubled in value this year and more than tripled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-reportedly-scraps-research-centre-in-uk/chwkKULRdut">Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone

According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$50.90
Prev Close	$53.96
Open	$54.25
Dividend Yield	0.00%
50-Day Moving Average	$50.49
Beta	1.87
Avg. Volume	29.3M
PE Ratio	67.53

52-Week High	$72.98
52-Week Low	$15.73
Market Capitalization	$12.2B
EPS (Annual)	$0.5322
Price to Book	21.65
Revenue Per Employee	$901,963.35
Enterprise Value/EBITDA	N/A

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMS Hims & Hers Health Inc